CN118215672A - 多肽偶联药物及其应用 - Google Patents
多肽偶联药物及其应用 Download PDFInfo
- Publication number
- CN118215672A CN118215672A CN202280052119.6A CN202280052119A CN118215672A CN 118215672 A CN118215672 A CN 118215672A CN 202280052119 A CN202280052119 A CN 202280052119A CN 118215672 A CN118215672 A CN 118215672A
- Authority
- CN
- China
- Prior art keywords
- trp
- pro
- cys
- 1nal
- dasp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 30
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 15
- 229920001184 polypeptide Polymers 0.000 title abstract description 14
- 238000010168 coupling process Methods 0.000 title description 8
- 230000008878 coupling Effects 0.000 title description 7
- 238000005859 coupling reaction Methods 0.000 title description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims description 51
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 102100035486 Nectin-4 Human genes 0.000 claims description 14
- 101710043865 Nectin-4 Proteins 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 12
- 239000003446 ligand Substances 0.000 claims description 10
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 31
- 239000007821 HATU Substances 0.000 description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000000126 substance Substances 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- ZHKQIADIIYMFOZ-UHFFFAOYSA-N 2-[9h-fluoren-9-ylmethoxycarbonyl(methyl)amino]acetic acid Chemical compound C1=CC=C2C(COC(=O)N(CC(O)=O)C)C3=CC=CC=C3C2=C1 ZHKQIADIIYMFOZ-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 159000000021 acetate salts Chemical class 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000011729 BALB/c nude mouse Methods 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- 125000005647 linker group Chemical group 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 4
- 101100028920 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cfp gene Proteins 0.000 description 4
- 101710176384 Peptide 1 Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 3
- 101001023705 Homo sapiens Nectin-4 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000002356 Nectin Human genes 0.000 description 3
- 108060005251 Nectin Proteins 0.000 description 3
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 102000043460 human nectin4 Human genes 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- KLBPUVPNPAJWHZ-UMSFTDKQSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KLBPUVPNPAJWHZ-UMSFTDKQSA-N 0.000 description 2
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 2
- ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 241000895503 Metrosideros Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 2
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 2
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- -1 hexafluorophosphate Chemical compound 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FODJWPHPWBKDON-LJQANCHMSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-LJQANCHMSA-N 0.000 description 1
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 1
- ORWNVJDLEMVDLV-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-naphthalen-1-ylpropanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(=O)O)CC1=CC=CC2=CC=CC=C12 ORWNVJDLEMVDLV-SANMLTNESA-N 0.000 description 1
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 1
- BUBGAUHBELNDEW-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfanylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCSC)C(O)=O)C3=CC=CC=C3C2=C1 BUBGAUHBELNDEW-SFHVURJKSA-N 0.000 description 1
- FKBGJLDYRSFHBT-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-tritylsulfanylbutanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CSC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 FKBGJLDYRSFHBT-DHUJRADRSA-N 0.000 description 1
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 1
- DOGZBRBJANHMLA-LJAQVGFWSA-N (2s)-6-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)hexanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCCNC(=N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C DOGZBRBJANHMLA-LJAQVGFWSA-N 0.000 description 1
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 1
- WPBXBYOKQUEIDW-VFNWGFHPSA-N (2s,4r)-1-(9h-fluoren-9-ylmethoxycarbonyl)-4-[(2-methylpropan-2-yl)oxy]pyrrolidine-2-carboxylic acid Chemical compound C1[C@H](OC(C)(C)C)C[C@@H](C(O)=O)N1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 WPBXBYOKQUEIDW-VFNWGFHPSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- VQNDBXJTIJKJPV-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridine Chemical compound C1=CC=NC2=NNN=C21 VQNDBXJTIJKJPV-UHFFFAOYSA-N 0.000 description 1
- LINBWYYLPWJQHE-UHFFFAOYSA-N 3-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCC(=O)O)C3=CC=CC=C3C2=C1 LINBWYYLPWJQHE-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-Tryptophan Natural products C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108091059809 PVRL4 Proteins 0.000 description 1
- 102100029740 Poliovirus receptor Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical group SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 229950004930 enfortumab vedotin Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 102000035035 immunoglobulin-like cell adhesion molecules Human genes 0.000 description 1
- 108091005483 immunoglobulin-like cell adhesion molecules Proteins 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 108010093470 monomethyl auristatin E Proteins 0.000 description 1
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 108010048507 poliovirus receptor Proteins 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 108010004034 stable plasma protein solution Proteins 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Peptides Or Proteins (AREA)
Abstract
一种多肽偶联药物及其应用,如式(I)所示化合物及其药学上可接受的盐,MMAE‑PABC‑Cit‑Val‑Glutaryl‑β‑Ala‑Sar10‑SEQ(I)。
Description
本申请主张如下优先权:
CN2021106108895,申请日:2021年6月1日;
CN2021108381694,申请日:2021年7月23日;
CN202111222422X,申请日:2021年10月20日。
本发明涉及一种多肽偶联药物及其应用,具体涉及式(I)所示化合物及其药学上可接受的盐。
2020年全球新增癌症病例约1930万例,死亡病例约1000万例,其中中国癌症死亡人数约300万,位居全球第一。肿瘤对传统治疗方式的耐药性以及对现有治疗方式的不敏感等原因,使得部分癌症患者尤其是晚期癌症患者的治疗手段有限且治疗效果并不理想。因此研究具有新靶点、新机制和新结构的肿瘤治疗药物始终是肿瘤治疗领域亟待解决的问题。
Nectin-4(poliovirus receptor like 4,PVRL4,结合素-4)是近年来新兴的肿瘤相关靶点,其隶属于nectin蛋白家族,主要有nectin 1-4四种亚型,与nectin-like分子(Necl)共同构成免疫球蛋白样细胞粘附分子,对细胞间粘附和紧密连接的形成和保持具有重要作用。Nectin 1,2,3广泛存在于人体正常组织中,nectin-4主要在胚胎和胎盘中高表达,在成年人体内表达量大幅度下降。研究表明,nectin-4在多种肿瘤中过度表达,如膀胱癌、尿路上皮癌、乳腺癌、三阴性乳腺癌、肺癌、胃癌、食道癌等,使其成为治疗相关癌症的潜在靶点。目前,针对该靶点研发的生物类抗体偶联药物Enfortumab vedotin已于2019年在美国批准上市,作为该靶点的唯一上市药物,其主要适应症被为转移型尿路上皮癌,同时另有多个适应症的临床有效性研究正在开展。因此开发以nectin-4为靶点的化学治疗药物具有广泛的应用前景。
发明内容
本发明提供了式(I)所示化合物或其药学上可接受的盐,
MMAE-PABC-Cit-Val-Glutaryl-β-Ala-Sar10-SEQ
(I)
其中,
SEQ由肽配体和连接子组成,所述肽配体以共价键形式与连接子相连;
肽配体包含被三个氨基酸残基隔开的两个环序列,所述两个环序列中的第一个为Pro-1Nal-dAsp,第二个为Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp;
氨基酸残基为Xi、Xii和Xiii,所述Xi、Xii和Xiii分别独立地选自Cys、hCys、βCys、Pen、Dap和N-methyl-Dap,且Xi、Xii和Xiii不全是Cys;
连接子选自
在本发明的一些方案中,上述肽配体选自:H-Xi-Pro-1Nal-dAsp-Xii-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Xiii-NH
2,其中,Xi、Xii和Xiii如本发明所定义。
在本发明的一些方案中,上述肽配体选自序列1-7:
H-hCys-Pro-1Nal-dAsp-Cys-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Cys-NH
2(序列1)、
H-Pen-Pro-1Nal-dAsp-Cys-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Cys-NH
2(序列2)、
H-Cys-Pro-1Nal-dAsp-Pen-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Cys-NH
2(序列3)、
H-Cys-Pro-1Nal-dAsp-Cys-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Pen-NH
2(序列4)、
H-Cys-Pro-1Nal-dAsp-hCys-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Cys-NH
2(序列5)、
H-Cys-Pro-1Nal-dAsp-Pen-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-hCys-NH
2(序列6)和
H-hCys-Pro-1Nal-dAsp-Pen-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Cys-NH
2(序列7),其他变量如本发明所定义。
在本发明的一些方案中,上述SEQ选自式(S-a)所示结构,
其中,Xi、Xii和Xiii如本发明所定义。
本发明还有一些方案由上述变量任意组合而来。
本发明还提供了下式所示化合物或其药学上可接受的盐,
MMAE-PABC-Cit-Val-Glutaryl-β-Ala-Sar10-hCys-Pro-1Nal-dAsp-Cys-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Cys-NH
2,TATA、
MMAE-PABC-Cit-Val-Glutaryl-β-Ala-Sar10-Pen-Pro-1Nal-dAsp-Cys-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Cys-NH
2,TATA、
MMAE-PABC-Cit-Val-Glutaryl-β-Ala-Sar10-Cys-Pro-1Nal-dAsp-Pen-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Cys-NH
2,TATA、
MMAE-PABC-Cit-Val-Glutaryl-β-Ala-Sar10-Cys-Pro-1Nal-dAsp-Cys-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Pen-NH
2,TATA、
MMAE-PABC-Cit-Val-Glutaryl-β-Ala-Sar10-Cys-Pro-1Nal-dAsp-hCys-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-
Trp-Cys-NH
2,TATA、
MMAE-PABC-Cit-Val-Glutaryl-β-Ala-Sar10-Cys-Pro-1Nal-dAsp-Pen-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-hCys-NH
2,TATA
和MMAE-PABC-Cit-Val-Glutaryl-β-Ala-Sar10-hCys-Pro-1Nal-dAsp-Pen-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Cys-NH
2,TATA。
本发明还提供了上述化合物或其药学上可接受的盐在制备治疗Nectin-4过表达的实体瘤的药物中的应用。
技术效果
本发明化合物与Nectin-4具有很强的结合作用,体内小鼠皮下瘤模型表现出强抑瘤效果。
定义和说明
除非另有说明,本文所用的下列术语和短语旨在具有下列含义。一个特定的术语或短语在没有特别定义的情况下不应该被认为是不确定的或不清楚的,而应该按照普通的含义去理解。当本文中出现商品名时,意在指代其对应的商品或其活性成分。
这里所采用的术语“药学上可接受的”,是针对那些化合物、材料、组合物和/或剂型而言,它们在可靠的医学判断的范围之内,适用于与人类和动物的组织接触使用,而没有过多的毒性、刺激性、过敏性反应或其它问题或并发症,与合理的利益/风险比相称。
术语“药学上可接受的盐”是指本发明化合物的盐,由本发明发现的具有特定取代基的化合物与相对无毒的酸或碱制备。当本发明的化合物中含有相对酸性的功能团时,可以通过在纯的溶液或合适的惰性溶剂中用足够量的碱与这类化合物接触的方式获得碱加成盐。药学上可接受的碱加成盐包括钠、钾、钙、铵、有机胺或镁盐或类似的盐。当本发明的化合物中含有相对碱性的官能团时,可以通过在纯的溶液或合适的惰性溶剂中用足够量的酸与这类化合物接触的方式获得酸加成盐。本发明的某些特定的化合物含有碱性和酸性的官能团,从而可以被转换成任一碱或酸加成盐。
本发明的药学上可接受的盐可由含有酸根或碱基的母体化合物通过常规化学方法合成。一般情况下,这样的盐的制备方法是:在水或有机溶剂或两者的混合物中,经由游离酸或碱形式的这些化合物与化学计 量的适当的碱或酸反应来制备。
“氨基酸”是指天然存在的和合成的氨基酸,以及起到与天然存在的氨基酸类似的作用的氨基酸类似物和氨基酸模拟物。天然存在的氨基酸是由遗传密码编码的那些氨基酸,以及后来修饰的那些氨基酸,例如,羟脯氨酸、γ-羧基谷氨酸和O-磷酸丝氨酸。氨基酸类似物是指具有与天然存在的氨基酸相同的基本化学结构(例如与氢、羧基基团、氨基基团和R基团结合的α碳)的化合物,例如高丝氨酸、正亮氨酸、甲硫氨酸亚砜、甲硫氨酸甲基锍。这样的类似物可以具有修饰的R基团(例如,正亮氨酸)或修饰的肽骨架,但保留与天然存在的氨基酸相同的基本化学结构。氨基酸模拟物是指其结构不同于一般的氨基酸化学结构,但起到与天然存在的氨基酸相似的作用的化学化合物。
本发明的氨基酸序列含有二十种天然氨基酸的标准单字母或三字母代码。
术语“治疗”包括抑制、减缓、停止或逆转现有症状或病患的进展或严重程度。
除非另有说明,术语“异构体”意在包括几何异构体、顺反异构体、立体异构体、对映异构体、旋光异构体、非对映异构体和互变异构体。
本发明的化合物可以存在特定的几何或立体异构体形式。本发明设想所有的这类化合物,包括顺式和反式异构体、(-)-和(+)-对映体、(R)-和(S)-对映体、非对映异构体、(D)-异构体、(L)-异构体,及其外消旋混合物和其他混合物,例如对映异构体或非对映体富集的混合物,所有这些混合物都属于本发明的范围之内。烷基等取代基中可存在另外的不对称碳原子。所有这些异构体以及它们的混合物,均包括在本发明的范围之内。
除非另有说明,术语“对映异构体”或者“旋光异构体”是指互为镜像关系的立体异构体。
除非另有说明,术语“顺反异构体”或者“几何异构体”系由因双键或者成环碳原子单键不能自由旋转而引起。
除非另有说明,术语“非对映异构体”是指分子具有两个或多个手性中心,并且分子间为非镜像的关系的立体异构体。
除非另有说明,“(+)”表示右旋,“(-)”表示左旋,“(±)”表示外消旋。
除非另有说明,用楔形实线键
和楔形虚线键
表示一个立体中心的绝对构型,用直形实线键
和直形虚线键
表示立体中心的相对构型,用波浪线
表示楔形实线键
或楔形虚线键
或用波浪线
表示直形实线键
或直形虚线键
除非另有说明,术语“富含一种异构体”、“异构体富集”、“富含一种对映体”或者“对映体富集”指其中一种异构体或对映体的含量小于100%,并且,该异构体或对映体的含量大于等于60%,或者大于等于70%,或者大于等于80%,或者大于等于90%,或者大于等于95%,或者大于等于96%,或者大于等于97%,或 者大于等于98%,或者大于等于99%,或者大于等于99.5%,或者大于等于99.6%,或者大于等于99.7%,或者大于等于99.8%,或者大于等于99.9%。
除非另有说明,术语“异构体过量”或“对映体过量”指两种异构体或两种对映体相对百分数之间的差值。例如,其中一种异构体或对映体的含量为90%,另一种异构体或对映体的含量为10%,则异构体或对映体过量(ee值)为80%。
可以通过的手性合成或手性试剂或者其他常规技术制备光学活性的(R)-和(S)-异构体以及D和L异构体。如果想得到本发明某化合物的一种对映体,可以通过不对称合成或者具有手性助剂的衍生作用来制备,其中将所得非对映体混合物分离,并且辅助基团裂开以提供纯的所需对映异构体。或者,当分子中含有碱性官能团(如氨基)或酸性官能团(如羧基)时,与适当的光学活性的酸或碱形成非对映异构体的盐,然后通过本领域所公知的常规方法进行非对映异构体拆分,然后回收得到纯的对映体。此外,对映异构体和非对映异构体的分离通常是通过使用色谱法完成的,所述色谱法采用手性固定相,并任选地与化学衍生法相结合(例如由胺生成氨基甲酸盐)。
本发明的化合物可以在一个或多个构成该化合物的原子上包含非天然比例的原子同位素。例如,可用放射性同位素标记化合物,比如氚(
3H),碘-125(
125I)或C-14(
14C)。又例如,可用重氢取代氢形成氘代药物,氘与碳构成的键比普通氢与碳构成的键更坚固,相比于未氘化药物,氘代药物有降低毒副作用、增加药物稳定性、增强疗效、延长药物生物半衰期等优势。本发明的化合物的所有同位素组成的变换,无论放射性与否,都包括在本发明的范围之内。
当所列举的连接基团没有指明其连接方向,其连接方向是任意的,例如,
中连接基团L为-M-W-,此时-M-W-既可以按与从左往右的读取顺序相同的方向连接环A和环B构成
也可以按照与从左往右的读取顺序相反的方向连接环A和环B构成
所述连接基团、取代基和/或其变体的组合只有在这样的组合会产生稳定的化合物的情况下才是被允许的。
除非另有规定,当某一基团具有一个或多个可连接位点时,该基团的任意一个或多个位点可以通过化学键与其他基团相连。当该化学键的连接方式是不定位的,且可连接位点存在H原子时,则连接化学键时,该位点的H原子的个数会随所连接化学键的个数而对应减少变成相应价数的基团。所述位点与其他基团连接的化学键可以用直形实线键
直形虚线键
或波浪线
表示。例如-OCH
3中的直形 实线键表示通过该基团中的氧原子与其他基团相连;
中的直形虚线键表示通过该基团中的氮原子的两端与其他基团相连。
本发明的化合物可以通过本领域技术人员所熟知的常规方法来确认结构,如果本发明涉及化合物的绝对构型,则该绝对构型可以通过本领域常规技术手段予以确证。例如单晶X射线衍射法(SXRD),把培养出的单晶用Bruker D8 venture衍射仪收集衍射强度数据,光源为CuKα辐射,扫描方式:
扫描,收集相关数据后,进一步采用直接法(Shelxs97)解析晶体结构,便可以确证绝对构型。
本发明的化合物可以通过本领域技术人员所熟知的多种合成方法来制备,包括下面列举的具体实施方式、其与其他化学合成方法的结合所形成的实施方式以及本领域技术上人员所熟知的等同替换方式,优选的实施方式包括但不限于本发明的实施例。
化合物依据本领域常规命名原则或者使用
软件命名,市售化合物采用供应商目录名称。
本发明所使用的溶剂可经市售获得。
本发明采用下述缩略词:eq.代表当量、等量;SPPS代表多肽固相合成法;TFA代表三氟乙酸;DIEA代表二异丙基乙基胺;DMF代表N,N-二甲基甲酰胺;HATU代表2-(7-氮杂苯并三氮唑)-N,N,N′,N′-四甲基脲六氟磷酸酯;EDC代表1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐;NHS代表N-羟基琥珀酰亚胺;TIS代表三异丙基硅烷;DTT代表DL-1,4-二硫代苏糖醇;MMAE代表单甲基奥瑞他汀E,具体结构为:
PABC代表
Cit代表L-瓜氨酸;Val代表L-缬氨酸;Glutaryl代表
β-Ala代表
Sar代表
Sar10代表
Cys代表L-半胱氨酸;hCys代表
βCys代表
Pen代表
N-methyl-Dap代表
1Nal代表1-萘丙氨酸;hArg代表L-高精氨酸;Hyp代表L-羟脯氨酸;Trp代表L-色氨酸;Pro代表L-脯氨酸;Thr代表L-苏氨酸;Ser代表L-丝氨酸;Asp代表L-天门冬氨酸;dAsp代表D-天门冬氨酸;Fmoc代表9-芴甲氧羰基;Boc代表叔丁氧基羰基(Boc);Trt代表三苯甲基;Pbf代表2,2,4,6,7-五甲基二氢苯并呋喃-5-磺酰基;PBS代表磷酸盐缓冲液。
下面通过实施例对本发明进行详细描述,但并不意味着对本发明任何不利限制。本文已经详细地描述了本发明,其中也公开了其具体实施例方式,对本领域的技术人员而言,在不脱离本发明精神和范围的情 况下针对本发明具体实施方式进行各种变化和改进将是显而易见的。
实施例1
合成路线:
步骤1:Peptide 1的TFA盐的合成
1.1多肽的偶联
该多肽使用标准的逐步合成方法合成。
1)将DMF加入到含有Rink amide MBHA树脂(0.5mmol,1.56g,sub:0.32mmol/g)的容器中并且让树脂溶胀2小时。
2)抽干,然后用DMF冲洗三次,每次氮气鼓动30秒。
3)加入20%哌啶/DMF,然后反应30min。缩合反应用显色反应进行检测,反应后用DMF冲洗树脂3~5次。
4)抽干,然后用DMF冲洗五次,每次氮气鼓动30秒。
5)加入下表原料1溶液,充氮30秒,然后加入缩合试剂,N
2鼓吹反应将近1小时。
6)重复步骤2至步骤5,每次顺序加入原料2-26缩合下一个氨基酸。详见表1。
表1加料顺序
# | 原料 | 偶联试剂 |
1 | Fmoc-Cys(Trt)-OH(3.0eq.) | HATU(2.85eq.)、DIEA(6.0eq.) |
2 | Fmoc-Trp(Boc)-OH(3.0eq.) | HATU(2.85eq.)、DIEA(6.0eq.) |
3 | Fmoc-HyP(tBu)-OH(3.0eq.) | HATU(2.85eq.)、DIEA(6.0eq.) |
4 | Fmoc-Pro-OH(3.0eq.) | HATU(2.85eq.)、DIEA(6.0eq.) |
5 | Fmoc-Thr(tBu)-OH(3.0eq.) | HATU(2.85eq.)、DIEA(6.0eq.) |
6 | Fmoc-Ser(tBu)-OH(3.0eq.) | HATU(2.85eq.)、DIEA(6.0eq.) |
7 | Fmoc-Trp(Boc)-OH(3.0eq.) | HATU(2.85eq.)、DIEA(6.0eq.) |
8 | Fmoc-Asp(OtBu)-OH(3.0eq.) | HATU(2.85eq.)、DIEA(6.0eq.) |
9 | Fmoc-hArg(Pbf)-OH(3.0eq.) | HATU(2.85eq.)、DIEA(6.0eq.) |
10 | Fmoc-Met-OH(3.0eq.) | HATU(2.85eq.)、DIEA(6.0eq.) |
11 | Fmoc-Cys(Trt)-OH(3.0eq.) | HATU(2.85eq.)、DIEA(6.0eq.) |
12 | Fmoc-dAsp(OtBu)-OH(3.0eq.) | HATU(2.85eq.)、DIEA(6.0eq.) |
13 | Fmoc-1Nal-OH(3.0eq.) | HATU(2.85eq.)、DIEA(6.0eq.) |
14 | Fmoc-Pro-OH(3.0eq.) | HATU(2.85eq.)、DIEA(6.0eq.) |
15 | Fmoc-hCys(Trt)-OH(2.0eq.) | HATU(1.90eq.)、DIEA(4.0eq.) |
16 | Fmoc-Sar-OH(5.0eq.) | HATU(4.75eq.)、DIEA(10.0eq.) |
17 | Fmoc-Sar-OH(5.0eq.) | HATU(4.75eq.)、DIEA(10.0eq.) |
18 | Fmoc-Sar-OH(5.0eq.) | HATU(4.75eq.)、DIEA(10.0eq.) |
19 | Fmoc-Sar-OH(5.0eq.) | HATU(4.75eq.)、DIEA(10.0eq.) |
20 | Fmoc-Sar-OH(5.0eq.) | HATU(4.75eq.)、DIEA(10.0eq.) |
21 | Fmoc-Sar-OH(5.0eq.) | HATU(4.75eq.)、DIEA(10.0eq.) |
22 | Fmoc-Sar-OH(5.0eq.) | HATU(4.75eq.)、DIEA(10.0eq.) |
23 | Fmoc-Sar-OH(5.0eq.) | HATU(4.75eq.)、DIEA(10.0eq.) |
24 | Fmoc-Sar-OH(5.0eq.) | HATU(4.75eq.)、DIEA(10.0eq.) |
25 | Fmoc-Sar-OH(5.0eq.) | HATU(4.75eq.)、DIEA(10.0eq.) |
26 | Fmoc-β-Ala-OH(3.0eq.) | HATU(2.85eq.)、DIEA(6.0eq.) |
其他直链多肽的合成方法与Peptide 1的TFA盐的合成方法相同。
1.2多肽切割和纯化
1)向含有侧链保护的多肽的烧瓶中加入切割缓冲溶液(90%TFA/2.5%TIS/2.5%H
2O/5.0%DTT),置于室温下搅拌2小时。
2)用冰的异丙醚将该多肽沉降出来,并用离心机(3min at 3000rpm)离心分离。
3)用异丙醚再洗两次。
4)干燥得Peptide 1的TFA盐。
步骤2:Peptide 2的TFA盐的合成
Peptide 1(0.7g,0.25mmol)溶解在50%CH
3CN/H
2O(1L)中,在室温下向搅拌着的溶液中缓慢加入TATA(95.9mg,0.38mmol),反应混合物在室温下搅拌30分钟,然后用NH
4HCO
3调节pH值到8,反应继续在室温搅拌12小时。LCMS显示反应完全,停止搅拌,通过反相制备(A:0.075%TFA水溶液,B:CH
3CN)进行纯化得到Peptide 2的TFA盐。
其他多肽的合成方法与Peptide 2的合成方法相似。
表2多肽序列表
步骤3:INT_1的TFA盐的合成
将化合物1-1(200.0mg,178.0μmol)溶于DMF(5mL)中,在0℃下加入DIEA(31.0μL,178.0μmol),搅拌10mins,同时将化合物1-2(290.4mg,890.1μmol)用另外一个反应瓶,也溶于DMF(5mL),在0℃下搅拌10mins,然后在0℃下将化合物1-1的反应液滴加到搅拌着的化合物1-2的反应液中,此反应液在0℃下搅拌30mins,将反应液过滤除去不溶的残渣,滤液直接用反相制备进行(TFA体系)纯化,得到化合物INT_1的TFA盐。
步骤4:PDC_1的乙酸盐的合成
将Peptide 2(50.0mg,16.8μmol)溶于DMF(0.3mL)中,然后加入DIEA(11.7μL,67.3μmol),在室温下搅拌10mins。接着将化合物INT_1(22.5mg,16.8μmol)溶于DMF(0.5mL)中,滴加到上述Peptide 2的反应液中,然后在室温下搅拌1小时,将反应液过滤除去不溶的残渣,滤液直接用反相制备(TFA体系)纯化,然后再通过制备转化成AcOH盐,得到PDC_1的乙酸盐。纯化条件见表3。
表3纯化条件
其他三个多肽偶联药物PDC_2-7的乙酸盐参考PDC_1的乙酸盐的合成(分别将原料替换为下表中的对应Peptide)得到,见表4。
表4 PDC结构信息
生物测试数据
测试例1本发明化合物与Nectin 4蛋白的结合能力测试
1.实验目的
用SPR法检测待测物与靶蛋白Nectin 4的亲和力。
2.材料和仪器
·Biacore 8K(GE Healthcare)
·96-well Plate(Cat#650101,greiner bio-one)
·CM5芯片(Cat#BR-1005-30,GE Healthcare)
·Amine Coupling Kit(Cat#BR-1000-50,GE Healthcare)
EDC
NHS
1M乙醇胺
·10mM醋酸钠pH4.5(Cat#BR-1003-50,GE Healthcare)
·DMSO(Cat#D4540,Sigma)
·P20(Cat#BR-1000-54,GE Healthcare)
·PBS(Cat#BR-1006-72,GE Healthcare)
·Nectin 4(Cat#1006-72,GE Healthcare)
3.实验方案
本实验采用氨基偶联法,即利用Biacore 8K将靶蛋白Nectin 4直接固定在CM5芯片上,然后将待测物作为分析物,用缓冲液(10mM PBS,pH7.4,137mM NaCl,2.7mM KCl,5%DMSO,0.05%P20)将待测物稀释到所需的浓度梯度,进行多循环动力学检测,每个循环进样180秒,解离180秒,然后再进行下一循环,获得靶蛋白Nectin 4与待测物的亲和力动力学分析数据。最终的数据用Biacore Insight Evaluation Software(V 2.0.15.12933)按1∶1模型进行Kinetics拟合分析。
4.实验方法及流程
1)配制缓冲液:10mM PBS,pH7.4,137mM NaCl,2.7mM KCl,5%DMSO,0.05%P20。
2)CM5芯片活化:用400mM EDC和100mM NHS以10μL/min的流速活化420秒。
3)靶蛋白偶联:用10mM醋酸钠(pH 4.5)将靶蛋白稀释到10μg/mL,以10μL/min的流速偶联284s。实验使用了芯片上的1#,2#和3#通道,偶联结果分别为1639.9RU,1747.8RU和1702.2RU。
4)CM5芯片封闭:用1M乙醇胺以10μL/min的流速封闭420秒。
5)分析物浓度:使用running buffer稀释待测物。待测物从100nM开始2倍梯度稀释至0.78nM。
6)进样分析:待测物工作液每个浓度为一个循环,以30μL/min的流速结合180秒,解离180秒。最后一个循环为5%DMSO溶剂校正循环。
7)所有结果按1∶1模型进行kinetics拟合分析。
5.实验结果
选取5个有效浓度的实验数据对本发明化合物用Biacore Insight Evaluation Software(V 2.0.15.12933)按1∶1模型进行Kinetics拟合分析,结果见表5:
表5本发明化合物与Human Nectin-4 SPR结合结果
化合物 | Human Nectin-4 SPR k D,nM(测试次数) |
PDC_1的乙酸盐 | 40.0(2) |
PDC_3的乙酸盐 | 3.0(3) |
PDC_4的乙酸盐 | 246.5(2) |
PDC_5的乙酸盐 | 80.7 |
PDC_6的乙酸盐 | 9.9(2) |
PDC_7的乙酸盐 | 3.3 |
若测试次数大于1则所列数值为多次测量的平均值。
结论:本发明化合物与Human Nectin-4蛋白具有强结合能力。
测试例2对人肺癌NCI-H292细胞皮下异种移植肿瘤BALB/c裸小鼠模型的体内药效学和PK研究
实验目的:评价本发明化合物在人肺癌NCI-H292细胞皮下异种移植肿瘤模型上的体内药效。
细胞培养:人肺癌NCI-H292细胞(ATCC,马纳萨斯,弗吉尼亚州,货号:CRL-1848)体外单层培养,培养条件为RPMI 1640培养基中加10%胎牛血清,100U/mL青霉素和100μg/mL链霉素,37℃ 5%CO
2孵箱培养。一周两次用胰酶-EDTA进行常规消化处理传代。当细胞饱和度为80%-90%,数量到达要求时,收取细胞,计数,接种。
动物:BALB/c裸小鼠,雌性,6-8周龄,体重17-21克。由北京维通利华公司提供。
肿瘤接种:将0.1mL(1×10
7个)NCI-H292细胞皮下接种于每只小鼠的右后背。
药物配制:化合物以25mM L-Histidine(pH=7)10%sucrose为溶媒配成均一溶液。用于IV(静注)组给药。
给药剂量为:3mg/kg。
实验指标:实验指标是考察肿瘤生长是否被抑制、延缓或治愈。每周两次用游标卡尺测量肿瘤直径。肿瘤体积的计算公式为:V=0.5a×b
2,a和b分别表示肿瘤的长径和短径。
化合物的抑瘤疗效用TGI(%)或相对肿瘤增殖率T/C(%)评价。TGI(%),反映肿瘤生长抑制率。TGI(%)的计算:TGI(%)=[(1-(某处理组给药结束时平均瘤体积-该处理组开始给药时平均瘤体积))/(溶剂对照组治疗结束时平均瘤体积-溶剂对照组开始治疗时平均瘤体积)]×100%。
相对肿瘤增殖率T/C(%):计算公式如下:T/C%=T
RTV/C
RTV×100%(T
RTV:治疗组RTV;C
RTV:阴性对照组RTV)。根据肿瘤测量的结果计算出相对肿瘤体积(relative tumor volume,RTV),计算公式为RTV =V
t/V
0,其中V
0是分组给药时(即d
0)测量所得平均肿瘤体积,Vt为某一次测量时的平均肿瘤体积,T
RTV与C
RTV取同一天数据。
在实验结束后将检测肿瘤重量,并计算T/Cweight百分比,Tweight和Cweight分别表示给药组和溶媒对照组的瘤重。
数据分析:T检验用于两组间比较。三组或多组间比较用one-way ANOVA。如果F值有显著性差异,应在ANOVA分析之后再进行多重比较。用SPSS 17.0进行所有数据分析。p<0.05认为有显著性差异。
结论:本发明化合物在人肺癌NCI-H292细胞皮下异种移植肿瘤BALB/c裸小鼠模型中展现出显著的抑瘤效果。
测试例3对人乳腺癌MDA-MB-468细胞皮下异种移植肿瘤BALB/c裸小鼠模型的体内药效学研究
实验目的:评价受试药BT8009和衍生物在人乳腺癌MDA-MB-468细胞皮下异种移植肿瘤模型上的体内药效。
细胞培养:人乳腺癌MDA-MB-468细胞(ATCC,马纳萨斯,弗吉尼亚州,货号:HTB-132)体外单层培养,培养条件为L-15培养基中加10%胎牛血清,100U/mL青霉素和100μg/mL链霉素,37℃,0%CO
2孵箱培养。一周两次用胰酶-EDTA进行常规消化处理传代。当细胞饱和度为80%-90%,数量到达要求时,收取细胞,计数,接种。
动物:BALB/c裸小鼠,雌性,6-8周龄,体重18-22克。由北京维通利华公司提供。
肿瘤接种:将0.2mL(1×10
7个)MDA-MB-468细胞(加基质胶,体积比为1∶1)皮下接种于每只小鼠的右后背。
药物配制:化合物以25mM L-Histidine(pH=7)10%sucrose为溶媒配成均一溶液。用于IV(静注)组给药。
给药剂量为:3mg/kg。
结论:本发明化合物在人乳腺癌MDA-MB-468细胞皮下异种移植肿瘤BALB/c裸小鼠模型中展现出显著的抑瘤效果。
Claims (7)
- 式(I)所示化合物或其药学上可接受的盐,MMAE-PABC-Cit-Val-Glutaryl-β-Ala-Sar10-SEQ(I)其中,SEQ由肽配体和连接子组成,所述肽配体以共价键形式与连接子相连;肽配体包含被三个氨基酸残基隔开的两个环序列,所述两个环序列中的第一个为Pro-1Nal-dAsp,第二个为Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp;氨基酸残基为Xi、Xii和Xiii,所述Xi、Xii和Xiii分别独立地选自Cys、hCys、βCys、Pen、Dap和N-methyl-Dap,且Xi、Xii和Xiii不全是Cys;连接子选自
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,肽配体选自:H-Xi-Pro-1Nal-dAsp-Xii-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Xiii-NH 2,其中,Xi、Xii和Xiii如权利要求1所定义。
- 根据权利要求2所述化合物或其药学上可接受的盐,其中,肽配体选自序列1-7:H-hCys-Pro-1Nal-dAsp-Cys-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Cys-NH 2(序列1)、H-Pen-Pro-1Nal-dAsp-Cys-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Cys-NH 2(序列2)、H-Cys-Pro-1Nal-dAsp-Pen-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Cys-NH 2(序列3)、H-Cys-Pro-1Nal-dAsp-Cys-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Pen-NH 2(序列4)、H-Cys-Pro-1Nal-dAsp-hCys-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Cys-NH 2(序列5)、H-Cys-Pro-1Nal-dAsp-Pen-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-hCys-NH 2(序列6)和H-hCys-Pro-1Nal-dAsp-Pen-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Cys-NH 2(序列7)。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,SEQ选自式(S-a)所示结构,其中,Xi、Xii和Xiii如权利要求1所定义。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,化合物选自式(I-1)所示结构,其中,Xi、Xii和Xiii如权利要求1所定义。
- 下列化合物或其药学上可接受的盐,MMAE-PABC-Cit-Val-Glutaryl-β-Ala-Sar10-hCys-Pro-1Nal-dAsp-Cys-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Cys-NH 2,TATA、MMAE-PABC-Cit-Val-Glutaryl-β-Ala-Sar10-Pen-Pro-1Nal-dAsp-Cys-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Cys-NH 2,TATA、MMAE-PABC-Cit-Val-Glutaryl-β-Ala-Sar10-Cys-Pro-1Nal-dAsp-Pen-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Cys-NH 2,TATA、MMAE-PABC-Cit-Val-Glutaryl-β-Ala-Sar10-Cys-Pro-1Nal-dAsp-Cys-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Pen-NH 2,TATA、MMAE-PABC-Cit-Val-Glutaryl-β-Ala-Sar10-Cys-Pro-1Nal-dAsp-hCys-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Cys-NH 2,TATA、MMAE-PABC-Cit-Val-Glutaryl-β-Ala-Sar10-Cys-Pro-1Nal-dAsp-Pen-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp- Trp-hCys-NH 2,TATA和MMAE-PABC-Cit-Val-Glutaryl-β-Ala-Sar10-hCys-Pro-1Nal-dAsp-Pen-Met-hArg-Asp-Trp-Ser-Thr-Pro-Hyp-Trp-Cys-NH 2,TATA。
- 权利要求1~6任意一项所述的化合物或其药学上可接受的盐在制备治疗Nectin-4过表达的实体瘤的药物中的应用。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021106108895 | 2021-06-01 | ||
CN202110610889 | 2021-06-01 | ||
CN2021108381694 | 2021-07-23 | ||
CN202110838169 | 2021-07-23 | ||
CN202111222422X | 2021-10-20 | ||
CN202111222422 | 2021-10-20 | ||
PCT/CN2022/094740 WO2022253051A1 (zh) | 2021-06-01 | 2022-05-24 | 多肽偶联药物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118215672A true CN118215672A (zh) | 2024-06-18 |
Family
ID=84323896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280052119.6A Pending CN118215672A (zh) | 2021-06-01 | 2022-05-24 | 多肽偶联药物及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN118215672A (zh) |
WO (1) | WO2022253051A1 (zh) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2373794A4 (en) * | 2008-12-12 | 2012-09-05 | Oncotherapy Science Inc | NECTINE-4 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS OF CANCER |
KR102459469B1 (ko) * | 2016-11-14 | 2022-10-26 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
JP2021520378A (ja) * | 2018-04-04 | 2021-08-19 | バイスクルテクス・リミテッド | ヘテロタンデム二環式ペプチド複合体 |
US11180531B2 (en) * | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
EP4038096A1 (en) * | 2019-10-03 | 2022-08-10 | BicycleTX Limited | Heterotandem bicyclic peptide complexes |
GB201914872D0 (en) * | 2019-10-15 | 2019-11-27 | Bicycletx Ltd | Bicyclic peptide ligand drug conjugates |
-
2022
- 2022-05-24 WO PCT/CN2022/094740 patent/WO2022253051A1/zh active Application Filing
- 2022-05-24 CN CN202280052119.6A patent/CN118215672A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2022253051A1 (zh) | 2022-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6942147B2 (ja) | Mt1−mmpに対して特異的な二環式ペプチド−毒素コンジュゲート | |
AU2008341661B2 (en) | An erythropoietin mimetic peptide derivatives and its pharmaceutical salt, the preparation and uses thereof | |
KR20190126294A (ko) | Mt1-mmp에 대한 결합용 펩티드 리간드 | |
US20060019900A1 (en) | Alpha-4 beta-1 integrin ligands for imaging and therapy | |
KR20180042442A (ko) | 방사성표지 her2 결합 펩티드 | |
EP0719790B1 (en) | Metal chelate forming peptides and use thereof | |
CN105579434A (zh) | 基于乙烯基砜的18f标记组合物和方法及其用途 | |
CA3027364A1 (en) | Alpha(v)beta(6) integrin-binding peptides and methods of use thereof | |
WO2001083693A2 (en) | Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses | |
JPH0288595A (ja) | 免疫刺激性ペプチド、その製法、及び該ペプチドを含有する薬剤組成物 | |
CN118215672A (zh) | 多肽偶联药物及其应用 | |
JP7221937B2 (ja) | 腫瘍標的化ペプチドバリアント | |
CN117015551B (zh) | 多肽的制备及其应用 | |
EP3433259B1 (en) | Conjugates of tacrolimus, their compositions, and their uses | |
CN118055772A (zh) | 三环多肽偶联药物及其应用 | |
CN117881430A (zh) | 具有新颖结构的多肽药物偶联物及其应用 | |
TW394777B (en) | Tumor affinity peptide, and radioactive diagnostic and radioactive therapeutic agent containing the peptide | |
TW202115101A (zh) | Cd38結合劑及其用途 | |
JP2016166151A (ja) | ペプチド化合物及びペプチド化合物の製造方法 | |
WO2024046469A1 (zh) | 环肽及其制备方法、包括其的复合物、及其用途 | |
CN118234743A (zh) | 含订合钉的多肽及其应用 | |
CN118307645A (zh) | 多肽的制备及其应用 | |
JPH0853494A (ja) | 腫瘍親和性ペプチド、該ペプチドを含有してなる放射性診断剤および放射性治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination |